Thorax

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rahman, I.
Right arrow Articles by MacNee, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rahman, I.
Right arrow Articles by MacNee, W.
Thorax 2000;55:189-193 ( March )

Is there any relationship between plasma antioxidant capacity and lung function in smokers and in patients with chronic obstructive pulmonary disease?

Irfan Rahmana, Elzbieta Swarskaa, Michael Henryb, Jan Stolkc, William MacNeea

a Respiratory Medicine Unit, Royal Infirmary, Edinburgh, UK, b Department of Medicine and Therapeutics, University College Dublin, Ireland, c Department of Pulmonology, Leiden University Medical Centre, Leiden, The Netherlands

Correspondence to: Professor W MacNee, ELEGI Colt Research Laboratories, Wilkie Building, Medical School, University of Edinburgh, Edinburgh EH8 9AG, UK

Received 2 March 1999; Returned to authors 4 June 1999; Revised version received 7 December 1999; Accepted for publication 8 December 1999

BACKGROUND---It has been suggested that oxidative stress is an important factor in the pathogenesis of chronic obstructive pulmonary disease (COPD). We have shown that an oxidant/antioxidant imbalance occurs in the distal air spaces of smokers and in patients with COPD which is reflected systemically in the plasma. A study was undertaken to determine whether plasma antioxidant status correlated with lung function as assessed by forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) in smokers and patients with COPD.
METHODS---Plasma antioxidant capacity, assessed by the Trolox equivalent antioxidant capacity (TEAC) as an index of overall systemic oxidative stress, and protein thiol levels were measured in 95 patients with stable COPD, in 82 healthy smokers, and in 37 healthy non-smokers.
RESULTS---Mean (SE) plasma TEAC levels were significantly decreased in patients with COPD (0.81 (0.03) mmol/l, p<0.001) and in healthy smokers (0.87 (0.04) mmol/l, p<0.001) compared with healthy non-smokers (1.31 (0.11) mmol/l). The mean differences in plasma antioxidant capacity (mM) were (0.81, 95% confidence interval (CI) 0.22 to 1.48), (0.87, 95% CI 0.2 to 1.46), and (1.31, 95% CI 1.09 to 1.58) in patients with COPD, healthy smokers, and healthy non-smokers, respectively. This reduction was associated with a 29% (95% CI 18 to 38) and a 30% (95% CI 19 to 40) decrease in plasma protein thiol levels in COPD patients and smokers, respectively. Current smoking was not the main contributor to the reduction in antioxidant capacity in patients with COPD as those patients who were still smokers had similar TEAC levels (mean (SE) 0.78 (0.05); n = 25) to those who had stopped smoking (0.84 (0.02); n = 70). No significant correlations were found between spirometric data measured as FEV1 % predicted or FEV1/FVC % predicted and the plasma levels of TEAC in patients with COPD, healthy smokers, or healthy non-smokers. Similarly, there was no significant correlation between FEV1 % predicted or FEV1/FVC % predicted and the levels of plasma protein thiols in the three groups.
CONCLUSIONS---These data confirm decreased antioxidant capacity in smokers and patients with COPD, indicating the presence of systemic oxidative stress. However, no relationship was found between protein thiols or TEAC levels and measurements of airflow limitation in either smokers or in patients with COPD.


Keywords: oxidants; antioxidants; protein thiols; smoking; chronic obstructive pulmonary disease


© 2000 by Thorax



This article has been cited by other articles:


Home page
Therapeutic Advances in Respiratory DiseaseHome page
I. Rahman
Review: Antioxidant therapeutic advances in COPD
Therapeutic Advances in Respiratory Disease, December 1, 2008; 2(6): 351 - 374.
[Abstract] [PDF]


Home page
ChestHome page
D. G. Yanbaeva, M. A. Dentener, E. C. Creutzberg, G. Wesseling, and E. F. M. Wouters
Systemic Effects of Smoking
Chest, May 1, 2007; 131(5): 1557 - 1566.
[Abstract] [Full Text] [PDF]


Home page
Am J EpidemiolHome page
H. M. Ochs-Balcom, B. J. B. Grant, P. Muti, C. T. Sempos, J. L. Freudenheim, R. W. Browne, M. Trevisan, L. Iacoviello, P. A. Cassano, and H. J. Schunemann
Oxidative Stress and Pulmonary Function in the General Population
Am. J. Epidemiol., December 15, 2005; 162(12): 1137 - 1145.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
S. A. A. Comhair, K. S. Ricci, M. Arroliga, A. R. Lara, R. A. Dweik, W. Song, S. L. Hazen, E. R. Bleecker, W. W. Busse, K. F. Chung, et al.
Correlation of Systemic Superoxide Dismutase Deficiency to Airflow Obstruction in Asthma
Am. J. Respir. Crit. Care Med., August 1, 2005; 172(3): 306 - 313.
[Abstract] [Full Text] [PDF]


Home page
Proc Am Thorac SocHome page
E. F. M. Wouters
Local and Systemic Inflammation in Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, April 1, 2005; 2(1): 26 - 33.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2000 BMJ Publishing Group Ltd & British Thoracic Society